| Q37060108 | A review of complementary and alternative approaches to immunomodulation |
| Q36699182 | Actual concept of "probiotics": is it more functional to science or business? |
| Q92619703 | Alteration of Gut Microbiota in Inflammatory Bowel Disease (IBD): Cause or Consequence? IBD Treatment Targeting the Gut Microbiome |
| Q37256009 | Anti-inflammatory activity of probiotic Bifidobacterium: enhancement of IL-10 production in peripheral blood mononuclear cells from ulcerative colitis patients and inhibition of IL-8 secretion in HT-29 cells |
| Q37684388 | Bacteriotherapy for inflammatory bowel disease: therapeutic tool and/or pharmacological vectors? |
| Q35750853 | Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. |
| Q37637093 | Bifidobacterium breve reduces apoptotic epithelial cell shedding in an exopolysaccharide and MyD88-dependent manner |
| Q36304789 | Biologic therapy for inflammatory bowel disease. |
| Q35832867 | Bugs and Guts: Practical Applications of Probiotics for Gastrointestinal Disorders in Children |
| Q39020374 | Capacity of lactic acid bacteria in immunity enhancement and cancer prevention. |
| Q33623573 | Capsular polysaccharide inhibits adhesion of Bifidobacterium longum 105-A to enterocyte-like Caco-2 cells and phagocytosis by macrophages |
| Q33557634 | Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN) |
| Q35609674 | Current therapy of ulcerative colitis in children |
| Q40399309 | Cytotoxicity of organic acids produced by anaerobic intestinal bacteria on cultured epithelial cells |
| Q37730870 | Diet and microbiota in inflammatory bowel disease: The gut in disharmony |
| Q26768564 | Diet therapy for inflammatory bowel diseases: The established and the new |
| Q92989345 | Dietary Composition and Effects in Inflammatory Bowel Disease |
| Q37842653 | Do probiotics offer opportunities to manipulate the periodontal oral microbiota? |
| Q55317992 | Effect of fermented vegetable beverage containing Pediococcus pentosaceus in patients with mild to moderate ulcerative colitis. |
| Q35865699 | Effect of microbial cell preparation on renal profile and liver function among type 2 diabetics: a randomized controlled trial |
| Q37118873 | Efficacy profiles for different concentrations of Lactobacillus acidophilus in experimental colitis |
| Q36039436 | Emerging drugs for the treatment of ulcerative colitis |
| Q34652744 | Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. |
| Q36415190 | Gastrointestinal microbiota and some children diseases: a review |
| Q36531260 | Gastrointestinal microflora: probiotics |
| Q38794312 | Gleaning Insights from Fecal Microbiota Transplantation and Probiotic Studies for the Rational Design of Combination Microbial Therapies. |
| Q37682520 | Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome |
| Q28238138 | Gut bacteria in health and disease |
| Q35963727 | Gut microbiome diversity in acute infective and chronic inflammatory gastrointestinal diseases in North India |
| Q35228714 | Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management |
| Q37858913 | Gut microbiota, probiotics and inflammatory bowel disease. |
| Q37082773 | Gut microflora: a new target for therapeutic approaches in inflammatory bowel disease |
| Q53231256 | High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. |
| Q64069149 | Human Gut Microbiome Response Induced by Fermented Dairy Product Intake in Healthy Volunteers |
| Q54404532 | Identification and quantification of viable Bifidobacterium breve strain Yakult in human faeces by using strain-specific primers and propidium monoazide |
| Q35031383 | Impact of probiotics on risk factors for cardiovascular diseases. A review |
| Q37544889 | Inflammatory disease processes and interactions with nutrition |
| Q37055823 | Integrative Therapies and Pediatric Inflammatory Bowel Disease: The Current Evidence |
| Q37345889 | Integrative medicine in gastrointestinal disease: evaluating the evidence |
| Q35245299 | Intestinal microbiota, probiotics and prebiotics in inflammatory bowel disease |
| Q37126537 | Is there any place for alimentary probiotics, prebiotics or synbiotics, for patients with inflammatory bowel disease? |
| Q53202351 | Isolation and Characterization of Putative Probiotic Bacterial Strain, Bacillus amyloliquefaciens, from North East Himalayan Soil Based on In Vitro and In Vivo Functional Properties. |
| Q54797083 | Isolation of Endotoxin Eliminating Lactic Acid Bacteria and a Property of Endotoxin Eliminating Protein. |
| Q40729014 | Latest concepts on the association between nonsteroidal anti-inflammatory drug-induced small intestinal injury and intestinal bacterial flora |
| Q26771287 | Microbiota Manipulation With Prebiotics and Probiotics in Patients Undergoing Stem Cell Transplantation |
| Q91650848 | Microbiota-gut-brain axis and its affect inflammatory bowel disease: Pathophysiological concepts and insights for clinicians |
| Q51684873 | Modulation of the effect of dextran sulfate sodium-induced acute colitis by the administration of different probiotic strains of Lactobacillus and Bifidobacterium. |
| Q46355559 | Neutralization of Lipopolysaccharide by Heat Shock Protein in Pediococcus pentosaceus AK-23. |
| Q42844195 | Non-pulmonary allergic diseases and inflammatory bowel disease: a qualitative review |
| Q35646449 | Nutraceutical Supplements for Inflammatory Bowel Disease |
| Q33572633 | Potential role of nutraceutical compounds in inflammatory bowel disease |
| Q73157927 | Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients |
| Q36000703 | Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon |
| Q47913026 | Probiotics and blueberry attenuate the severity of dextran sulfate sodium (DSS)-induced colitis |
| Q38125810 | Probiotics and clinical effects: is the number what counts? |
| Q35987864 | Probiotics and gastrointestinal diseases |
| Q34013030 | Probiotics and prebiotics in chronic inflammatory bowel diseases |
| Q34588415 | Probiotics and prebiotics in inflammatory bowel disease: microflora 'on the scope'. |
| Q33788552 | Probiotics and the gastrointestinal tract: where are we in 2005? |
| Q39179063 | Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review |
| Q90020877 | Probiotics for induction of remission in ulcerative colitis |
| Q24242963 | Probiotics for induction of remission in ulcerative colitis |
| Q34616408 | Probiotics for maintaining remission of ulcerative colitis in adults |
| Q90020870 | Probiotics for maintenance of remission in ulcerative colitis |
| Q24234400 | Probiotics for maintenance of remission in ulcerative colitis |
| Q82416873 | Probiotics in Gastrointestinal Disorders |
| Q37071265 | Probiotics in clinical practice: an overview |
| Q27002496 | Probiotics in inflammatory bowel diseases and associated conditions |
| Q37492720 | Probiotics in pediatric inflammatory bowel diseases |
| Q59120479 | Probiotics in the Management of Inflammatory Bowel Diseases? |
| Q34637436 | Probiotics in the gastrointestinal diseases of the elderly. |
| Q33438518 | Probiotics in the management of colonic disorders |
| Q36348570 | Probiotics in the management of inflammatory bowel disease. |
| Q34637606 | Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients |
| Q38970657 | Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders. |
| Q35744173 | Probiotics, prebiotics and child health: where are we going? |
| Q35122167 | Probiotics, prebiotics and the gastrointestinal tract in health and disease |
| Q37647493 | Probiotics, prebiotics, synbiotics and naturally fermented foods: why more may be more |
| Q36441502 | Probiotics: their role in the treatment and prevention of disease |
| Q45104385 | Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats |
| Q45166043 | Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis |
| Q38702350 | Rationale for Using of Bifidobacterium Probiotic Strains-Fermented Milk Against Colitis Based on Animal Experiments and Clinical Trials |
| Q37345932 | Rationale for probiotic treatment strategies in inflammatory bowel disease |
| Q44544446 | Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis |
| Q40094968 | Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis |
| Q35140710 | Restoring the gut microbiome for the treatment of inflammatory bowel diseases |
| Q37032747 | Review article: Probiotics in gastrointestinal and liver diseases |
| Q33223485 | Review article: bifidobacteria as probiotic agents -- physiological effects and clinical benefits |
| Q35880365 | Review article: gut flora and inflammatory bowel disease. |
| Q37216699 | Review article: new drug formulations, chemical entities and therapeutic approaches for the management of ulcerative colitis |
| Q46284784 | Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. |
| Q33256876 | Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease |
| Q91761608 | Side Effects Associated with Probiotic Use in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials |
| Q28254207 | Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease |
| Q26784194 | Th17 Cells as Potential Probiotic Therapeutic Targets in Inflammatory Bowel Diseases |
| Q64257282 | The Efficacy of Probiotics, Prebiotic Inulin-Type Fructans, and Synbiotics in Human Ulcerative Colitis: A Systematic Review and Meta-Analysis |
| Q38026552 | The emerging therapeutic role of probiotics in inflammatory bowel disease |
| Q35446516 | The gut microbiota and inflammatory bowel disease |
| Q38164343 | The immunomodulatory effect of probiotics beyond atopy: an update |
| Q36653913 | The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. |
| Q27001546 | The role of probiotic lactic acid bacteria and bifidobacteria in the prevention and treatment of inflammatory bowel disease and other related diseases: a systematic review of randomized human clinical trials |
| Q57245618 | The use of probiotics in gastrointestinal diseases |
| Q26853628 | Use of gnotobiotic mice to identify and characterize key microbes responsible for the development of the intestinal immune system |
| Q37823328 | Use of probiotics in gastrointestinal disorders: what to recommend? |
| Q59120549 | VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis |
| Q36563414 | VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases |
| Q37759115 | What is the evidence for the use of probiotics in the treatment of inflammatory bowel disease? |
| Q82974598 | [Nutritional therapy in inflammatory bowel disease] |